Literature DB >> 35261673

Carcinoid Tumors: from the Past into the Future.

Tariq Hameed1, Awadh Kumar2, Chandra Bhushan Singh1.   

Abstract

Carcinoids are a rare and slow growing tumor, having a propensity to affect all organs but most commonly involve the gastrointestinal tract, followed by lungs. Carcinoid tumors secrete a variety of peptides and neuroamines. Though clinical presentation is varied and depends on the involved organ along with produced neuroactive amines, common symptoms include flushing, explosive watery diarrhoea and bronchospasm. Estimation of 5-HIAA in 24-hour urine is highly specific. Serum chromogranin is highly sensitive even in non-secretory carcinoids. Octreoscan along with MIBG is a better diagnostic modality as compared to computed tomography or magnetic resonance imaging alone. Treatment involves a multidisciplinary approach, including resection of primary tumor and debulking, embolisation of liver carcinoids, somatostatin analogues and chemotherapy. Molecular target therapy with Sunitinib and Bevacizumab have been shown to have a promising role in treatment, with higher response rate and slower progression.

Entities:  

Year:  2021        PMID: 35261673      PMCID: PMC8897795          DOI: 10.26574/maedica.2020.16.4.695

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  27 in total

Review 1.  Therapeutic options for gastrointestinal carcinoids.

Authors:  Irvin M Modlin; Igor Latich; Mark Kidd; Michelle Zikusoka; Geeta Eick
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05       Impact factor: 11.382

2.  Bronchial carcinoid--twenty years' experience defines a selective surgical approach.

Authors:  T S Chughtai; J E Morin; N M Sheiner; J A Wilson; D S Mulder
Journal:  Surgery       Date:  1997-10       Impact factor: 3.982

Review 3.  Carcinoid tumors.

Authors:  Rebecca S Sippel; Herbert Chen
Journal:  Surg Oncol Clin N Am       Date:  2006-07       Impact factor: 3.495

4.  Malignancies of the appendix: beyond case series reports.

Authors:  Marcia L McGory; Melinda A Maggard; Hakjung Kang; Jessica B O'Connell; Clifford Y Ko
Journal:  Dis Colon Rectum       Date:  2005-12       Impact factor: 4.585

Review 5.  Treatment of advanced carcinoid tumors.

Authors:  Alysandra Lal; Herbert Chen
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

Review 6.  Tumor markers in neuroendocrine tumors.

Authors:  B Eriksson; K Oberg; M Stridsberg
Journal:  Digestion       Date:  2000       Impact factor: 3.216

Review 7.  Neuroendocrine tumours: clinical presentation and management of localized disease.

Authors:  Matthew H Kulke
Journal:  Cancer Treat Rev       Date:  2003-10       Impact factor: 12.111

8.  Carcinoid tumors of the lung.

Authors:  N Okike; P E Bernatz; L B Woolner
Journal:  Ann Thorac Surg       Date:  1976-09       Impact factor: 4.330

9.  Cognitive impairment associated with carcinoid syndrome.

Authors:  Janice L Pasieka; R Stewart Longman; Anthony J Chambers; Otto Rorstad; Kathy Rach-Longman; Elijah Dixon
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

10.  Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.

Authors:  J Maroun; W Kocha; L Kvols; G Bjarnason; E Chen; C Germond; S Hanna; P Poitras; D Rayson; R Reid; J Rivera; A Roy; A Shah; L Sideris; L Siu; R Wong
Journal:  Curr Oncol       Date:  2006-04       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.